TL;DR
This retrospective study compares lung and bronchus cancer mortality rates in New York (a Medicaid expansion state) and Mississippi (a non-expansion state) before and after the Affordable Care Act (ACA). The findings reveal that while lung cancer mortality decreased nationwide, the decline was significantly more pronounced in New York, suggesting that state-level policy decisions regarding healthcare access directly correlate with cancer survival outcomes.
What Problem Does This Paper Address?
Lung and bronchus cancer remains one of the most prevalent and deadly forms of cancer in the United States. While medical advancements have improved treatment options, access to early diagnosis and consistent care is often dictated by insurance status.
The authors set out to investigate whether the Affordable Care Act—specifically the expansion of Medicaid—had a measurable impact on mortality. By comparing two states with vastly different approaches to the ACA (New York, which embraced expansion, and Mississippi, which did not), the researchers aimed to determine if broader insurance coverage translates into fewer cancer deaths at a population level.
Methods
The researchers conducted a retrospective analysis comparing two distinct five-year windows:
- Pre-ACA: 2009–2013
- Post-ACA: 2015–2019 (using 2014 as the implementation buffer year)
To ensure a rigorous comparison, they utilized:
- Chi-square tests: To determine the statistical significance of mortality changes within and between the states and the total U.S. population.
- Infrastructure Adjustments: The study accounted for pre-existing differences in healthcare infrastructure, such as per-capita healthcare spending and private insurance coverage rates, to isolate the impact of the ACA as much as possible.
- Scaling: For the statistical software to process the data correctly, mortality-to-population percentages were multiplied by 100,000 (effectively looking at deaths per 100,000 people).
Datasets
The study relied on high-quality, aggregated public health data:
- CDC WONDER Database: This serves as the primary source, integrating data from the National Program of Cancer Registries (NPCR), the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program, and the National Vital Statistics System (NVSS).
- 2010 U.S. Census Data: Used to establish population denominators for calculating mortality percentages.
Key Insights and Ideas
- The "Great Divergence": Before the ACA (2009–2013), there was no statistically significant difference in the trend of lung cancer mortality between Mississippi, New York, and the U.S. average. They were essentially on the same trajectory.
- Policy as a Life-Saver: After 2014, a sharp divergence occurred. While all groups saw improvements, the rate of decline in New York was significantly steeper than in Mississippi or the U.S. as a whole.
- The Medicaid Expansion Factor: The authors argue that the primary driver for New York’s superior performance was the expansion of Medicaid, which likely facilitated earlier detection and better access to the expensive, specialized therapies required for lung cancer.
- Infrastructure vs. Policy: Even though New York started with higher per-capita healthcare spending ($8,759 vs. Mississippi's $6,554 in 2010), the disproportionate improvement post-2014 suggests the policy change provided a boost beyond what existing infrastructure alone could explain.
Key Results
The quantitative results highlight a clear benefit for the expansion state:
- New York: Mortality decreased from 0.004691% to 0.004088% (p < 0.0001), representing the greatest percent decline among the studied groups.
- Mississippi: Mortality decreased from 0.006537% to 0.006282% (p = 0.0061). While statistically significant, the magnitude of the drop was much smaller than New York's.
- Total U.S.: The national average saw a decrease from 0.05097% to 0.0473% (p < 0.0001).
- Post-ACA Comparison: In the 2015–2019 window, the difference in the rate of decline between the three venues was statistically significant (p < 0.002), with the expansion state leading the way.
Limitations and Future Work
The authors acknowledge several constraints that provide a roadmap for future research:
- Ecological Fallacy: Because the data is aggregated at the state level, the study cannot definitively link an individual’s survival to their specific insurance status (e.g., whether a specific person who survived had Medicaid vs. private insurance).
- Confounding Variables: Factors such as regional smoking cessation rates, environmental pollutants, and the varying density of specialized imaging centers or oncologists were not fully controlled for in this preliminary study.
- Next Steps: The researchers plan to follow this work with a multivariate analysis to better account for these confounders, including the density of healthcare providers and the availability of specific new cancer therapies by insurance plan.
Summary updated